Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New CAR t therapy aims to control Hard-to-Treat multiple myeloma

NCT ID NCT07510100

First seen Apr 03, 2026 · Last updated May 20, 2026 · Updated 8 times

Summary

This early-stage study tests a new treatment called Equecabtagene Autoleucel (a CAR T-cell therapy) for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, which are modified in a lab to target and attack cancer cells. The study will enroll 17 participants to check for side effects and see how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Institute of Science Tokyo Hospital

    Bunkyo-ku, Tokyo, 113-8519, Japan

    Contact

  • Japanese Red Cross Medical Center

    Shibuya-ku, Tokyo, 150-8935, Japan

    Contact

  • Nihon University Itabashi Hospital

    Itabashi-ku, Tokyo, 173-8610, Japan

    Contact

Conditions

Explore the condition pages connected to this study.